AU3079895A - Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies - Google Patents

Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies

Info

Publication number
AU3079895A
AU3079895A AU30798/95A AU3079895A AU3079895A AU 3079895 A AU3079895 A AU 3079895A AU 30798/95 A AU30798/95 A AU 30798/95A AU 3079895 A AU3079895 A AU 3079895A AU 3079895 A AU3079895 A AU 3079895A
Authority
AU
Australia
Prior art keywords
immunonanoparticles
beta
coated
monoclonal antibodies
microglobulin monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30798/95A
Inventor
Pascal Breton
Nicole Bru-Magniez
Jean-Claude Chermann
Xavier Guillon
Francois Lescure
Jean-Marie Teulon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
UPSA SAS
Original Assignee
UNION PHARMA SCIENT APPL
Institut National de la Sante et de la Recherche Medicale INSERM
UPSA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNION PHARMA SCIENT APPL, Institut National de la Sante et de la Recherche Medicale INSERM, UPSA SAS filed Critical UNION PHARMA SCIENT APPL
Publication of AU3079895A publication Critical patent/AU3079895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
AU30798/95A 1994-07-18 1995-07-18 Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies Abandoned AU3079895A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9408852A FR2722411B1 (en) 1994-07-18 1994-07-18 IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION
FR9408852 1994-07-18
PCT/FR1995/000960 WO1996002278A1 (en) 1994-07-18 1995-07-18 Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies

Publications (1)

Publication Number Publication Date
AU3079895A true AU3079895A (en) 1996-02-16

Family

ID=9465475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30798/95A Abandoned AU3079895A (en) 1994-07-18 1995-07-18 Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies

Country Status (3)

Country Link
AU (1) AU3079895A (en)
FR (1) FR2722411B1 (en)
WO (1) WO1996002278A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755136B1 (en) * 1996-10-25 1999-01-22 Virsol PROCESS FOR THE PREPARATION OF METHYLIDENE MALONATE NANOPARTICLES, NANOPARTICLES CONTAINING ONE OR MORE BIOLOGICALLY ACTIVE MOLECULES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2774096B1 (en) * 1998-01-29 2000-04-07 Virsol NOVEL SURFACTANT COPOLYMERS BASED ON METHYLIDENE MALONATE
FR2789314B1 (en) * 1999-02-09 2001-04-27 Virsol WOUND SUTURE MATERIAL BASED ON METHYLIDENE MALONATE
CN116687969A (en) 2015-05-18 2023-09-05 小利兰·斯坦福大学托管委员会 Methods and compositions for treating aging-related injuries
CN109666072B (en) * 2018-12-28 2022-04-05 江苏众红生物工程创药研究院有限公司 Anti-human beta2-microglobulin antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264766A (en) * 1877-09-19 1981-04-28 Hoffmann-La Roche Inc. Immunological diagnostic reagents
WO1992011846A1 (en) * 1991-01-07 1992-07-23 St George's Enterprises Limited Particulates
EP0695312A1 (en) * 1993-04-22 1996-02-07 Laboratoires Upsa Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation thereof

Also Published As

Publication number Publication date
FR2722411B1 (en) 1996-10-04
FR2722411A1 (en) 1996-01-19
WO1996002278A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU3811495A (en) Antibodies
AU5869596A (en) Anti-gp130 monoclonal antibodies
AU4992997A (en) Humanized anti-cd11a antibodies
IL128406A0 (en) Monoclonal antibodies
AU4025193A (en) Humanized C-erbB-2 specific antibodies
AU4618193A (en) Humanized antibodies
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
AU2391195A (en) Lymphocyte activation antigens and antibodies thereto
AU6080794A (en) Antibodies directed against binding-associated epitopes
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU5732694A (en) Humanized antibodies reactive with cd18
AU2645297A (en) Hepatitis b monoclonal antibodies
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
AU3330689A (en) Monoclonal antibodies
AU7449296A (en) Monoclonal antibodies to potato, tomato and eggplant glycoalkaloids and assays for the same
EP0909278A4 (en) Nephropathy-related immunoglobulin g and antibodies for same
AU3079895A (en) Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
AU8547291A (en) Monoclonal antibodies against tenascin
AU2041095A (en) Separation-fee specific binding assays using anti-inhibitor antibodies
AU1809695A (en) Tumor associated monoclonal antibody 123av16
GB9718911D0 (en) Monoclonal antibodies
AU4400396A (en) Anti-tpo monoclonal antibody
AU2652897A (en) Anti-human mp52 monoclonal antibody
AU6404696A (en) Nephropathy-related immunoglobulin g and antibodies for same